You are here:

Archived: rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro)

Advice

Following a full submission.

Rotigotine (Neupro) is not recommended for use within NHS Scotland for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa).

Rotigotine was superior to placebo in two randomised controlled trials. However, in one active comparator study non-inferiority to another non-ergolinic dopamine agonist comparator was not shown. The economic case has not been demonstrated.

Drug Details

Drug Name: rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro)
SMC Drug ID: 289/06
Manufacturer: Schwarz Pharma Ltd
Indication: Early-stage idiopathic Parkinson’s disease as monotherapy
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 7 August 2006

Current Advice

Resubmission 9 July 2007

Back